Abstract
Headache is a neurological disorder with a high disabling potential and high prevalence. Headaches are estimated to affect nearly a billion cases worldwide. Migraines have a significant effect on patients’ quality of life, especially when attacks become frequent. To overcome this burden, the scientific society provided guidelines that could guide physicians in their approach to patients with headache in both diagnosis and treatment. Several studies have been conducted in the research field of acute and preventive therapy of headache and adherence to the guidelines represents a useful tool to guarantee the patient the best standard of care. However, compliance with the guidelines remains extremely low. This chapter provides a schematic methodology that helps physicians in the approach to the migraine patient by referring to the most recent guidelines describing the characteristics of the patients and the different therapeutic possibilities. Finally, readers will be provided with guidance to help improve the quality of migraine clinical trials and to inform clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Pescador Ruschel MA, De Jesus O. Migraine headache. StatPearls Publishing; 2022.
Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lantéri-Minet M, Braschinsky M, Del Rio MS, Daniel O, Özge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–14. https://doi.org/10.1038/s41582-021-00509-5.
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–57.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.
Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87. https://doi.org/10.1016/S1474-4422(16)30293-9.
GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1603–58. https://doi.org/10.1016/S0140-6736(16)31460-X.
Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422–35. https://doi.org/10.1016/S0025-6196(11)60561-2.
Latinovic R, Gulliford M, Ridsdale L. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry. 2006;77(3):385–7.
Alpuente A, Tassorelli C, Diener HC, Silberstein SD, Pozo-Rosich P. Have the IHS guidelines for controlled trials of acute treatment of migraine attacks been followed? Laying the ground for the 4th edition. Cephalalgia. 2020;40(8):778–87. https://doi.org/10.1177/0333102420906843.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202.
https://www.sisc.it/upload/Linee-Guida-Cefalee-Parte-1-1421315319650-4221.pdf
Mitsikostas DD, Ashina M, Craven A, Diener HC, Goadsby PJ, Ferrari MD, Lampl C, Paemeleire K, Pascual J, Siva A, Olesen J, Osipova V, Martelletti P. European Headache Federation consensus on technical investigation for primary headache disorders. J Headache Pain. 2015;17:5. https://doi.org/10.1186/s10194-016-0596-y.
Metso TM, Tatlisumak T, Debette S, Dallongeville J, Engelter ST, Lyrer PA, Thijs V, Bersano A, Abboud S, Leys D, Grond Ginsbach C, Kloss M, Touzé E, Pezzini A, Metso AJ, CADISP Group. Migraine in cervical artery dissection and ischemic stroke patients. Neurology. 2012;78:1221–8.
Joubert J. Diagnosing headache. Aust Fam Physician. 2005;34(8):621–5.
Becker WJ, Findlay T, Moga C, Scott NA, Harstall C, Taenzer P. Guideline for primary care management of headache in adults. Can Fam Physician. 2015;61(8):670–9.
Simmaco M, Borro M, Missori S, Martelletti P. Pharmacogenomics in migraine: catching biomarkers for predictable disease control. Expert Rev Neurother. 2009;9(9):1267–9.
Belyaeva II, Subbotina AG, Eremenko II, Tarasov VV, Chubarev VN, Schiöth HB, Mwinyi J. Pharmacogenetics in primary headache disorders. Front Pharmacol. 2021;12:820214. eCollection 2021. https://doi.org/10.3389/fphar.2021.820214.
Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57. https://doi.org/10.1186/s10194-018-0899-2.
Tassorelli C, Diener HC, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38:815–32.
Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia. 2019;39:687–710.
Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37. https://doi.org/10.1186/s10194-019-0974-3. Erratum in: J Headache Pain. 2019 May 17;20(1):55
Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33(3):309–15. https://doi.org/10.1097/WCO.0000000000000806.
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–98. https://doi.org/10.1001/jama.2019.16711. Erratum in: JAMA. 2020 Apr 7;323(13):1318
Martelletti P, Luciani M, Spuntarelli V, Bentivegna E. Deprescribing in migraine. Expert Opin Drug Saf. 2021;20(6):623–5. https://doi.org/10.1080/14740338.2021.1907342.
IHS. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11:1–12.
Mitsikostas DD, Belesioti I, Arvaniti C, et al. Patients’ preferences for headache acute and preventive treatment. J Headache Pain. 2017;18:102.
Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, Damico D, Diener H-C, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32(1):6–38.
Macedo A, Farré M, Baños JE. A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur J Clin Pharmacol. 2006;62(3):161–72. https://doi.org/10.1007/s00228-005-0088-5.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Guideline for good clinical practice. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed 29 May 2017.
International Committee of Medical Journal Editors. Defining the role of authors and contributors. http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html. Accessed 25 Nov 2018.
Diener H-C, Tassorelli C, Diener H-C, Dodick DW, International Headache Society Clinical Trials Committee, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine adults. Cephalalgia. 2020;40(10):1026–44.
Diener H-C, Tassorelli C, Diener H-C, Dodick DW, International Headache Society Clinical Trials Standing Committee, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine adults. Cephalalgia. 2018;38(5):815–32.
Acknowledgments
n/a
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
This paper was not funded.
Declaration of Interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript.
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Gaglianone, C., Bentivegna, E., Martelletti, P. (2023). What Is the Best Methodology for Headache or Migraine Research?. In: Yalınay Dikmen, P., Özge, A. (eds) Clinical Scales for Headache Disorders. Headache. Springer, Cham. https://doi.org/10.1007/978-3-031-25938-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-031-25938-8_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-25937-1
Online ISBN: 978-3-031-25938-8
eBook Packages: MedicineMedicine (R0)